Emmaus Life Sciences, Inc. EMMA

Company Overview

Emmaus Life Sciences, Inc. is a U.S.-based biopharmaceutical company focused on the treatment and management of rare and orphan diseases. The company’s primary commercial activity centers on therapies for sickle cell disease (SCD), with operations spanning drug development, commercialization, and related healthcare support services. Emmaus operates within the biotechnology and specialty pharmaceutical industries and derives the majority of its revenue from the sale of prescription therapeutics and associated healthcare products.

The company is best known for developing and commercializing Endari® (L-glutamine oral powder), an FDA-approved prescription treatment designed to reduce acute complications associated with sickle cell disease in adult and pediatric patients. Emmaus evolved from earlier healthcare and nutritional science initiatives and transitioned into a publicly traded biotechnology company focused on rare disease therapeutics. Its strategic positioning has historically emphasized underserved patient populations, orphan-drug market opportunities, and specialized treatment channels within hematology and chronic genetic disorders.